Custom Search Insider Trading Activity Insider Trading Activity
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Custom Search Insider Trading Activity
Updated Sep 5, 2024
Ticker
|
Company Name
|
Qty.
|
Price
|
Size ($)
|
Filing Date
|
Type
|
Δ Own
|
Own
|
Insider Names
|
Title
|
Trade Dates
|
Is Scheduled
| |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Spyre Therapeutics, Inc.
| -18.53K |
$28.17 | -$522,073.86 | -13.73% | 116.42K |
Sep 3
| |||||||
Spyre Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
|
Feb 1
| |||||||
Spyre Therapeutics, Inc.
| 134.95K |
—
|
—
|
∞
| 134.95K |
Dec 22
| |||||||
Aeglea Biotherapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
|
Sep 1
| |||||||
Aeglea Biotherapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
| ||||||||
Arcutis Biotherapeutics, Inc.
| -291.00 |
$15.26 | -$4,441.65 | -0.49% | 59.12K |
Mar 6
|
Scheduled
| ||||||
Arcutis Biotherapeutics, Inc.
| 21K |
—
|
—
| +54.68% | 59.41K |
Mar 2
| |||||||
Arcutis Biotherapeutics, Inc.
| -1.85K |
$15.90 | -$29,421.25 | -4.60% | 38.41K |
Feb 28 - Mar 2
|
Scheduled
| ||||||
Arcutis Biotherapeutics, Inc.
| 5K |
$1.68 | $8,403.00 | +14.18% | 40.26K |
Sep 16
| |||||||
Arcutis Biotherapeutics, Inc.
| 13K |
$16.85 | -$5,104.17 | +58.39% | 35.26K |
Mar 3 - Mar 7
|
Scheduled
| ||||||
Arcutis Biotherapeutics, Inc.
| -420.00 |
$17.75 | -$7,456.13 | -1.85% | 22.26K |
Mar 1
|
Scheduled
| ||||||
Arcutis Biotherapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
|
Dec 30
| |||||||
Arcutis Biotherapeutics, Inc.
| -12.56K |
$20.07 | -$252,139.49 | -35.64% | 22.68K |
Dec 27
|
Scheduled
| ||||||
Arcutis Biotherapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
|
Apr 1
| |||||||
Arcutis Biotherapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
| ||||||||
It looks like there's no data for these filter options. Maybe you'll be interested in these options instead. | |||||||||||||